amcure

amcure, a spin-off from the Karlsruhe Institute of Technology, develops AM001 as first-in-class compound. AM001’s mode of action differs fundamentally from known experimental or approved compounds for the inhibition of angiogenesis and metastasis in cancer therapy, which in most cases either address only a single RTK o